Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer
Autore:
Sukin, SW; Chhikara, M; Zhu, XH; Ayala, G; Aguilar, LK; Smith, EO; Miles, BJ; Thompson, TC; Kadmon, D; Aguilar-Cordova, E;
Indirizzi:
Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 ott Dept Urol, Houston, TX 77030 USA Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 , Dept Pediat, Houston, TX 77030 USA Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 Gene Therapy, Houston, TX 77030 USA Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 , Dept Pathol, Houston, TX 77030 USA Advantagene Inc, San Diego, CA 92024 USA Advantagene Inc San Diego CA USA92024 agene Inc, San Diego, CA 92024 USA
Titolo Testata:
MOLECULAR THERAPY
fascicolo: 4, volume: 3, anno: 2001,
pagine: 500 - 506
SICI:
1525-0016(200104)3:4<500:IVSRPA>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
VIRUS THYMIDINE KINASE; ORTHOTOPIC MOUSE MODEL; RADICAL PROSTATECTOMY; BREAST-CANCER; GANCICLOVIR THERAPY; RECURRENCE RATES; ANTIGEN; VECTORS;
Keywords:
gene therapy; mammary; prostate;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Aguilar-Cordova, E Harvard Univ, Sch Med, Harvard Gene Therapy Initiat, 4 Blackfan Circle,Suite 407, Boston, MA 02115 USA Harvard Univ 4 Blackfan Circle,Suite 407 Boston MA USA 02115
Citazione:
S.W. Sukin et al., "In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer", MOL THER, 3(4), 2001, pp. 500-506

Abstract

Adenoviral-mediated gene therapy delivery, combining the herpes simplex virus thymidine kinase gene (Ad-tk) with gancyclovir, has been evaluated as atreatment modality for numerous tumors in the laboratory and in the clinics. As a single modality, gene therapy has shown some promising local and systemic results but no curative success. Surgery is the standard of care formany solid tumors. However, minor residual tumor following surgical resection can lead to local recurrence, and surgery is neither efficient nor plausible for metastatic disease. In this study, two tumor models were used to evaluate the effects of Ad-tk gene therapy as an adjuvant to surgery. Subcutaneous mammary- and prostate-derived tumors were produced in syngeneic mice. To evaluate systemic effects, tumor cells were injected intravenously, with subsequent formation of lung nodules. The subcutaneous tumors were surgically resected and the tumor bed was bathed with saline or Ad-tk. The animals were evaluated for toxicity, local tumor recurrence, survival, and lungnodule formation. No evidence of additional toxicity was observed. In the less aggressive mammary model, the time to recurrence was increased from 11.7 (+/-1.0) days to 22.7 (+/-5.5) days. In the prostate model, recurrence went from a mean of 17.3 (+/-5.6) to 22.6 (+/-6.8) days. Survival was also improved from a mean of 19.7 (+/-1.1) to 32.3 (+/-4.8) and 26.1 (+/-5.0) to 34.1 (+/-6.1) days in the mammary and prostate models, respectively. Evidence of systemic benefits from the use of adjuvant Ad-tk therapy was demonstrated by a significant reduction in lung nodules from a mean of 17 to 3.5. These results suggest that Ad-tk gene therapy may be a useful adjuvant for patients undergoing surgery for treatment of cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/07/20 alle ore 01:08:52